No Data
Guanhao Biotech (300238.SZ): The company currently has no Brain-computer Interface related business.
Gelonghui, February 26丨 Guanhao Biotech (300238.SZ) stated on the investor interaction platform that the company currently has no Brain-computer Interface related Business.
Guanhao Biotech (300238.SZ): Application for issuing stocks to specific entities accepted by Shenzhen Stock Exchange.
On February 24th, Gelonghui reported that Guanhao Biotech (300238.SZ) announced that it received a notice from the Shenzhen Stock Exchange on February 21, 2025, regarding the acceptance of the application documents for the issuance of stocks to specific objects (Shenzhen Stock Review [2025] No. 30). The Shenzhen Stock Exchange has verified the application documents submitted by the company for the issuance of stocks to specific objects, deemed the application documents complete, and decided to accept them.
Guanhao Biotech (300238.SZ): Currently, the company's phase III clinical trial for bemodipine for atopic dermatitis is actively underway.
On February 19, Gelonghui reported that Guanhao Biotech (300238.SZ) stated on the investor interactive platform that the Phase III clinical trial of its bemomotizumab for atopic dermatitis is currently being actively conducted. The company will fulfill its information disclosure obligations in a timely manner in strict accordance with the relevant regulations of the Securities Regulatory Commission based on subsequent progress.
Guanhao Biotech (300238.SZ): Appointed Zhao Feng as General Manager.
On January 10, Guanhao Biotech (300238.SZ) announced that the Board of Directors recently received the resignation letter submitted by Mr. Zhang Yongming. To better fulfill the responsibilities of the Chairman, Mr. Zhang Yongming is applying to resign from the position of General Manager to devote more energy to the company's Global Strategy and governance. After resigning, Mr. Zhang Yongming will continue to serve as the Chairman of the Sixth Board of Directors, Chairman of the Strategic Committee, member of the Nomination Committee, and member of the Compensation and Assessment Committee. The company held the eleventh meeting of the Sixth Board of Directors on January 10, 2025, to review and approve the appointment of the company’s general manager.
Is Guanhao Biotech Co.,Ltd.'s (SZSE:300238) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
guanhao biotech (300238.SZ): the company has temporarily suspended the CAR-T project
On November 4th, Guanhao Biotech (300238.SZ) stated on the investor interaction platform that the company has temporarily suspended the CAR-T project.
Guanhao BiotechLtd (SZSE:300238) Delivers Shareholders Notable 7.1% CAGR Over 5 Years, Surging 12% in the Last Week Alone